Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present ANI Pharmaceuticals, Inc. (NASDAQ: ANIP).

Full DD Report for ANIP

You must become a subscriber to view this report.


Recent News from (NASDAQ: ANIP)

ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q1 2018 Results - Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q1 2018 Earnings Conference Call May 08, 2018 10:30 AM ET Executives Arthur Przybyl - CEO, President and Director Stephen Carey - CFO and VP of Finance Analysts Dewey Steadman - Canaccord Elliot Wilbur - Raymond James Presentation Ope...
Source: SeekingAlpha
Date: May, 08 2018 21:07
ANI Pharmaceuticals beats by $0.04, misses on revenue
ANI Pharmaceuticals (NASDAQ: ANIP ): Q1 EPS of $1.32 beats by $0.04 . Revenue of $46.5M (+26.9% Y/Y) misses by $3.43M . Press Release More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 08 2018 08:33
ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance
BAUDETTE, Minn. , May 8, 2018 /PRNewswire/ -- For the first quarter 2018: Net revenues of $46.5 million , an increase of 27% as compared to the same period in 2017 GAAP net income of $2.3 million and diluted GAAP earnings per share of $0.19 Adjusted non-GAAP EBITDA ...
Source: PR Newswire
Date: May, 08 2018 08:30
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn. , May 7, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal P...
Source: PR Newswire
Date: May, 07 2018 08:30
Market Trends Toward New Normal in Viacom, Nutanix, ANI Pharmaceuticals, PACCAR, Cabot Oil & Gas, and Box - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Viacom Inc. (NASDAQ:VIAB), Nutanix Inc. (NASDAQ:NTNX), ANI Pharmaceuticals...
Source: GlobeNewswire
Date: May, 07 2018 07:55
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
BAUDETTE, Minn. , May 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2018 financial results on Tuesday, May 8, 2018 , before the opening of the U.S. financial markets. The earnings press release...
Source: PR Newswire
Date: May, 01 2018 08:30
Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up
Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh...
Source: SeekingAlpha
Date: April, 30 2018 08:00
ANI Pharmaceuticals buying assets from Amneal, Impax
ANI Pharmaceuticals (NASDAQ: ANIP ) has signed definitive deals to acquire generic products and assets from Amneal Pharmaceuticals and Impax Laboratories (NASDAQ: IPXL ) for cash. More news on: ANI Pharmaceuticals, Inc., Impax Laboratories, Inc., Healthcare stocks news, Merger & acqu...
Source: SeekingAlpha
Date: April, 27 2018 19:13
Amneal And Impax Receive FTC Clearance For Business Combination
BRIDGEWATER, N.J. , April 27, 2018 /PRNewswire/ --  Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Federal Trade Commission (FTC) has cleared the Amneal and Impax business combination, subject to Amneal and Impax's agreement to...
Source: PR Newswire
Date: April, 27 2018 18:50
ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn. , April 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has signed definitive agreements to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ...
Source: PR Newswire
Date: April, 27 2018 18:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1862.8264.6164.9962.3984,179
2018-05-1762.8264.6164.9962.3984,179
2017-06-2045.8545.7946.3044.61188,002
2017-06-1945.6845.9946.423745.65118,358
2017-06-1644.8445.2845.5744.619997,230

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-185,80811,67349.7558Short
2018-05-1713,22222,48758.7984Short
2018-05-1611,51834,47733.4078Cover
2018-05-155,68312,90544.0372Short
2018-05-1411,22220,40454.9990Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ANIP.


About ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)

Logo for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante s hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. The company also is developing its calcium phosphate nanotechnology CAP for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin.

 

Contact Information

 

 

Current Management

  • Stephen M. Simes / President, CEO

Current Share Structure

  • Market Cap: $721,913,433 - 05/11/2018
  • Issue and Outstanding: 11,651,282 - 02/20/2018

 


Recent Filings from (NASDAQ: ANIP)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 06 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018

 

 


Daily Technical Chart for (NASDAQ: ANIP)

Daily Technical Chart for (NASDAQ: ANIP)


Stay tuned for daily updates and more on (NASDAQ: ANIP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ANIP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ANIP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ANIP and does not buy, sell, or trade any shares of ANIP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/